Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).

被引：0
|
作者：
Ryan, Charles J.
Kim, Won
Buettner, Arden
Britton, Susan Lynne
Lankford, Maria L.
Neely, Doug B.
Green, Mark R.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Xcenda, Tampa, FL USA
[4] Xcenda, Palm Harbor, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] The effect of docetaxel, enzalutamide, abiraterone, and radium-223 on cognitive function in older men with metastatic castrate-resistant prostate cancer (mCRPC)
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Hansen, Aaron Richard
    Joshua, Anthony M.
    Warde, Padraig Richard
    Gregg, Richard William
    Fleshner, Neil Eric
    Tomlinson, George
    Hotte, Sebastien J.
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
    Gordoa, Teresa Alonso
    Goodman, Michael Moses
    Vulsteke, Christof
    Roubaud, Guilhem
    Zhang, Jingsong
    Parikh, Mamta
    Piulats, Josep M.
    Azaro, Analia
    James, Gareth D.
    Cavazzina, Riccardo
    Gangl, Eric
    Thompson, Jeff
    Pouliot, Gayle Pageau
    Kumar, Rakesh
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] Second-line prescribing preferences (PPrefs) of US-based medical oncologists' (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC).
    Ryan, Charles J.
    Green, Mark R.
    Britton, Susan L.
    Buettner, Arden
    Lankford, Maria
    Neely, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [35] Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
    Vankayala, Hema M.
    Heilbrun, Lance K.
    Dobson, Kimberlee
    Stark, Karri
    Li, Jing
    Smith, Daryn W.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Strauss, Julius
    Chun, Guinevere
    Couvillon, Anna
    Harold, Nancy
    Chen, Clara
    Dawson, Nancy Ann
    Apolo, Andrea Borghese
    Steinberg, Seth M.
    Trepel, Jane B.
    Wright, John Joseph
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for choice of therapy after failure of first-line FOLFOX plus bevacizumab (FFB) in patients with metastatic colorectal cancer (MCC).
    Bendell, Johanna C.
    Britton, Susan L.
    Lankford, Maria
    Buettner, Arden
    Green, Mark R.
    Neely, Douglas
    Scharf, Mitchell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel
    Cushen, Samantha J.
    Power, Derek G.
    Murphy, Kevin P.
    McDermott, Ray
    Griffin, Brendan T.
    Lim, Marvin
    Daly, Louise
    MacEneaney, Peter
    Sullivan, Kathleen O'
    Prado, Carla M.
    Ryan, Aoife M.
    CLINICAL NUTRITION ESPEN, 2016, 13 : E39 - E45
  • [39] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Peltekian, Sophie
    Sajwani, Shellyza
    Wang, Xiang
    Kanji, Salmaan
    SUPPORTIVE CARE IN CANCER, 2023, 31 (05)
  • [40] Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel
    Sophie Peltekian
    Shellyza Sajwani
    Xiang Wang
    Salmaan Kanji
    Supportive Care in Cancer, 2023, 31
12345